Artificial Intelligence in early detection of Adverse Drug Reaction for Anti-psychotic drugs

Abstract

Impact of Adverse Drug Reactions (ADRs) is a major cause of concern with major economic and emotional consequences to different stakeholders like pharmaceutical companies, patients and even Governments. The development of new antipsychotic drugs is a long and extremely expensive process. The average development of Antipsychotic drugs is 7-10 years and costs millions of dollars to bring a new antipsychotic drug to market. One of the biggest challenges to this long and expensive frame is ADRs. Considering the conceptualization of the drug to its final delivery to patients is complex and time consuming, use of advanced technologies like Artificial Intelligence can be a game changer and a win-win situation for all stakeholders. This review article aims to highlight the use of artificial intelligence (AI) in discovery and development of antipsychotic drugs with focus on the “Pre-Clinical Research” phase.